Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

- 9 Month Interim Analysis of Open-label Study to be Presented at  a Major Scientific Conference in July 2021 as an Oral Presentation -

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

Anavex Life Sciences

Prothena

3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases

American Airlines

AMC Entertainment

GameStop

Zomedica

These high-flying stocks may soon reverse course.

5 Ultra-Popular Stocks to Avoid Like the Plague in April

Blink Charging

Being able to scout for future growth potential is a crucial pillar of investing success.

3 Best Contrarian Stocks to Buy Now

Bionano Genomics

Ocugen, Inc.

These stocks have been unstoppable since late December -- but will they stay that way?

5 High-Flying Stocks That Turned $200,000 Into More Than $1 Million in 3 Months

Is (SAVA) Outperforming Other Medical Stocks This Year?

Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?

Cassava Sciences simufilam produced an improvement in ADAS-cog scores of 1.6 points at 6 months.

Anavex And Cassava Sciences: Closer To An Understanding Of Alzheimer's Disease

AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021.

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

A potential new treatment for Alzheimer's disease could be worth billions.

Should You Buy Cassava Sciences Stock Now?

Birks Group

Express

Koss

Marathon Digital Holdings

Novavax

Sino-Global Shipping America

If nothing happens – and that's the hope – this article will be nothing but a good laugh. However, astute investors should at least know about these stocks that could crash.

7 High-Flying Stocks That Could Crash 20% or Even More

The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimers, has seen a 7% rise over the last ten trading days, while it is up 1% over the last five trading days. However, the stock has gained a whopping 666% year-to-date.

Can Rally In Cassava Sciences Stock Continue?

Rubius Therapeutics Inc

Here's why these attention-grabbing stocks could be toxic to your portfolio.

3 Biotech Stocks to Avoid Right Now

Uber

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Why SAVA Stock And UBER Stock Are Moving Wednesday

Riot Blockchain

Silvergate Capital Corp

Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.

A Year Into the COVID-19 Pandemic: 5 Stock Winners

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer's disease.

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

Promising results for the company's lead Alzheimer's drug have made Cassava one of 2021's most exciting stocks.

Why Cassava Sciences Stock Skyrocketed 145.1% in February

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9th, and Wednesday, March 10th, 2021. Management is scheduled to present and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

Simufilam should receive Breakthrough Therapy Designation in Alzheimer's disease soon. That could mean a number of bullish outcomes.

Cassava Sciences Can Get To Market Early In Alzheimer's

SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer's disease study. The post Why Cassava Sciences Has Tremendous Upside Potential appeared first on InvestorPlace.

Why Cassava Sciences Has Tremendous Upside Potential

Cassava Sciences will likely be a winner in the fight against Alzheimer's. If successful, SAVA stock is worth significantly more.

Cassava Sciences Looks Like It Will Be a Winner In Fighting Alzheimer's

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?

AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference.

News for Cassava Sciences Inc Stock (SAVA)